搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
MedPage Today
2 小时
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...
4 小时
on MSN
Clinical trials reveal combining inhibitors shows promise in chronic lymphocytic leukemia
A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...
healthandpharma
17 小时
Fixed-Duration Acalabrutinib Plus Venetoclax Achieves Superior 77% PFS in Untreated CLL ...
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
The Pharma Letter
5 小时
ASH 2024: Adding to Calquence to venetoclax improves PFS in CLL
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...
Cure Today
7 天
‘The Future Is Bright’ for R/R CLL Treatment Landscape
Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...
Armed robbery in Revesby
1 天
Novel Triplet Therapy Shows Promise in High-Risk CLL
Researchers at Dana-Farber Cancer Institute are presenting a promising advance in the treatment of chronic lymphocytic ...
The American Journal of Managed Care
7 天
New Guidelines Clarify EORTC Quality of Life Scores for Chronic Lymphocytic Leukemia
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...
Targeted Oncology
12 天
The Clinical Utility of Genetic Risk Scores in Chronic Lymphocytic Leukemia
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
FiercePharma
1 天
ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
The American Journal of Managed Care
13 天
Real-World Data Confirm Ibrutinib's Role in Relapsed CLL
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...
5 天
on MSN
Miracle leukaemia drug trial offers fresh hope to new cancer patients
Grandad William Bennett, 69, was diagnosed with chronic lymphocytic leukaemia (CLL) 12 years ago, a type of blood cancer ...
Oncology Nurse Advisor
12 天
Relapsed/Refractory CLL: Which Treatments Are the Safest?
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈